Article
Protease‐activated receptor 4: from structure to function and back again
5 Feb 2016
Abstract excerpt
Protease-activated receptors are a family of four GPCRs (PAR1-PAR4) with a number of unique attributes. Nearly two and a half decades after the discovery of the first PAR, an antagonist targeting this receptor has been approved for human use. The first-in-class PAR1 antagonist, vorapaxar, was approved for use in the USA in 2014 for the prevention of thrombotic cardiovascular events in patients with a history of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
